Neuronetics, Inc. (NASDAQ:STIM) director and 10% owner Jorey Chernett executed a series of open-market transactions between November 6 and November 13, 2026, selling common stock valued at approximately $4.48 million and purchasing shares worth $79,600, according to a Form 4 filing.
The disposals totaled 3,335,411 shares, with prices spanning $1.15 to $2.39. The acquisition involved 40,000 shares at prices between $1.98 and $2.00. The trades unfolded against a backdrop of sharp stock weakness: shares have dropped 35% over the past week and were last at $1.39, roughly 60% below the 52-week high of $3.44, based on data referenced in the filing coverage. Despite the selloff, analysts maintain price targets in the $5 to $7 range.
The filing breaks down the transactions as follows:
- November 6, 2026: 250,804 shares sold at a weighted average price of $2.39, with individual trades from $2.16 to $2.56.
- November 9, 2026: 103,959 shares sold at a weighted average price of $2.06, with prices from $1.96 to $2.18. On the same day, 40,000 shares were purchased at a weighted average price of $1.99, with trades from $1.98 to $2.00.
- November 11, 2026: 86,757 shares sold at a weighted average price of $1.61, with prices from $1.59 to $1.65.
- November 12, 2026: 706,840 shares sold at a weighted average price of $1.43, with prices from $1.39 to $1.54.
- November 13, 2026: 2,187,051 shares sold at a weighted average price of $1.15, with prices from $1.15 to $1.44.
After these transactions, Chernett beneficially owns 7,325,577 shares of Neuronetics common stock.
The Form 4 noted that the transactions are considered matchable under Section 16(b) of the Securities Exchange Act of 1934, and Chernett intends to disgorge any short-swing profit to Neuronetics. The filing also indicated that it constitutes an exit filing for Chernett.
All prices reported are weighted average prices. Chernett has undertaken to provide full information regarding the number of shares sold or purchased at each separate price upon request.
In other recent news, Neuronetics reported third-quarter 2026 results that surpassed Wall Street expectations. The company recorded an adjusted loss of $0.02 per share, compared with an anticipated loss of $0.09 per share. Revenue also exceeded forecasts, reaching $42 million versus the expected $40.43 million. These results point to stronger margins and improving operating performance, contributing to Neuronetics' ongoing progress toward profitability. The company's financial performance has drawn investor attention, reflecting positive sentiment in the market. The recent developments highlight Neuronetics' ability to outperform earnings and revenue estimates. This performance could lead to increased interest from analysts and investors alike.